Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on

Stephen I Pelton1, Ron Dagan, Beverly M Gaines

  • 1Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.

Vaccine
|March 18, 2003
PubMed

Insights

Pneumococcal conjugate vaccines, like the seven-valent formulation (PCV13), are crucial for preventing infant disease. Ongoing research tracks vaccine safety, effectiveness in vulnerable populations, and impact on antibiotic resistance.

Area of Science:

  • Immunology
  • Pediatrics
  • Infectious Diseases

Background:

  • Streptococcus pneumoniae causes significant infant illness globally.
  • Antibiotic resistance necessitates vaccine development for prevention.
  • The current seven-valent pneumococcal conjugate vaccine (PCV7) is widely used.

Framework:

  • This paper summarizes a symposium on pneumococcal conjugate vaccines.
  • Discussions included PCV7 safety, efficacy in premature infants, and impact on colonization.
  • Evaluation of replacement disease, resistance rates, and updated recommendations were covered.

Implementation:

  • Postmarketing surveillance of PCV7 safety.
  • Clinical trials assessing vaccine impact in diverse infant populations.
  • Analysis of direct and indirect effects on pneumococcal colonization and transmission.

Implications:

  • Understanding PCV7's role in reducing disease burden and antibiotic resistance.
  • Informing vaccination strategies and recommendations for infants and young children.
  • Assessing the broader public health impact of conjugate vaccines in Europe and Asia-Pacific.

Related Concept Videos

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...